Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQ tree SLIT-tablet in children and adolescents with birch-group pollen allergic rhinoconjunctivitis
NL-OMON51039Phase 3Active, not recruiting
- Sponsor
- ALK-Abelló
- Start
- Sep 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic conjunctivitis (AC) and allergic rhinoconjunctivitis (ARC) comparing SQ tree SLIT-tablet with Placebo (2 arms). Primary endpoint: Average allergic rhinoconjunctivitis daily total combined score during birch pollen season. Started Sep 2022; status: active, not recruiting.
02
Drugs
birch pollen allergen extract
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NL-OMON51039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51039.